I. Introduction
Magnetic resonance guided high intensity focused ultrasound (MRgFUS ) therapy of fibroids is a proven technique approved by US Food and Drug administration for treatment of fibroids by heat generated using high intensity ultrasound. 4 Advantages of MRgFUS include: rapid resolution of uterine fibroids symptoms, short recoverytimes, fewer post-operative complications compared with UAE or hysterectomy, and a low incidence of complications. 17 It can improve fibroid related symptoms and cause shrinkage of fibroids in due course of time. The purpose of this study is to prove the clinical efficacy of this procedure in patients with symptomatic fibroids using clinical symptom severity scoring (SSS) before the procedure and after 6 to 12 months follow up.
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III. Methods Of Enrollment
All patients who met the eligibility criteria ,were screened for MR compatibility like cardiacpacemaker,metallic implants and severe claustrophobia.The patient must be able to lie prone for about 3 hours and must be able to communicate sensations during the procedure.Importance was given to scars in the abdomen as they may disrupt the passage of US waves.In our study,all suitable subjects were given questionnaires for symptom severity scoring which were assigned a score on a 4 point scale.No symptoms-score 0,Mild symptoms-score 1,moderate symptoms-score 2,severe symptoms-score 3.These are subjective measurements for evaluation and monitoring.
Preprocedure Mri
The purpose of this screening MRI was: ➢ To confirm the diagnosis. ➢ To exclude associated adenomyosis,adnexal mass. ➢ To assess the exact number of fibroids,size,location and enhancement characters.
Small fibroids <3cm and large fibroids >10 cm were not included due to inability to target them or achieve necrosis. ➢ The path of Ultrasound beam:If fibroid was >12cm from the anterior abdominal wall,US waves may not penetrate the target.If it is very close to the sacrum,heating the sacral bone may lead to sciatic nerve injury.Sonications must be limited to atleast 4cm from the sacral bone.All intervening or adjacent organs in the treatment path as well as scars must be avoided.
Ideal patient is one with
Anterior fibroid with uniform to low signal intensity,no intervening organ in pathway and with good perfusion.
Mrgfus Procedure:
The MRI-guided focused ultrasound therapy systems used in this study PHILIPS Sonalleve MR HIFU integrates with Achieva 1.5 T MR system to enable focused ultrasound therapy to be planned Directly With Mr Images And To Give Real-Time Mr Thermometry Imaging After Each Sonication.
Preprocedure Preparation:
• Patient were instructed to fast atleast for 6 hours before the procedure.Ideal would be fasting for 12 hours.
• Abdomen was well cleaned and shaved from the umbilicus to one cm below the pubic bone to prevent any air bubbles trapped in hair which may increase the risk of burns.
• Conscious sedation with midazolam was given to alleviate anxiety and pain such that the patient was responsive throughout.
• Informed oral and written consent was obtained from all the participants after proper counseling about the procedure.
• Continuous bladder drainage was kept to keep the bladder empty because filling of the bladder during the procedure may displace the uterus and change the position of fibroids.
• Patient was given a PANIC BUTTON during treatment such that she can stop the treatment when she has severe pain or heat sensation.
Treatment Planning:
Patient was made to lie down in prone position such that her abdomen was in contact with acoustic gel pad in a waterbath of degassed and deionized water.Prior to initiating the procedure multiplanar T 2 Wimages were taken and transferred for planning program.Region of treatment(ROT) was manually drawn and defined within the capsule of the fibroid.
Treatment areas were selected as small cells (Fig 2) of varying sizes ranging from 4mm to 32mm. Each cell was checked for safety in near field and far field. The cells were arranged in different clusters to cover the treatment area. (Fig 3) Prospective Target volume was analysed with superimposed US beam paths in 3 planes.The beam path must be angled for optimal access of the fibroid such that scars,air bubbles and other intervening organs are avoided.If fibroid was close to the serosalsurface,a 0.5cm margin of nontargeted tissue should be maintained to prevent thermal damage to tissues in close proximity.
Procedure:
After thermal imaging and marking the region of treatment,the procedure begins with delivery of subtherapeutic doses of low power sonication(50-100W) to the centre of fibroid.Real time thermometry was acquired through proton resonance frequency shift method. Resultant images were provided for sonication location to reconfirm targeting accuracy. A pre sonication image obtained was used as baseline and further images were added sequentially in a single sonication .Colourcodings (Blue to red scale) (Fig 4) representing the gradual increase in temperature were projected over the treatment area . Special graph showing the temperature rise was also made available on the screen. Next sonication was done after the lapse of reasonable cooling time. The sonication parameters were safely adjusted using the thermometry graphs for further safe sonications. Subsequent sonications were given at therapeutic power level.Until therapeutic thermal dose,energy delivered was increased to coagulate the tissue at temperatures above 60 o C.It is desirable to try and reach 70-80 o C that ensures tissue necrosis.Each sonication lasts for 20-40seconds.Between each sonication adequate cooling time should be given of upto 90seconds to avoid thermal buildup which will damage the surrounding tissues.
For all planned sonications the same procedure was continued.To ensure no complications,continuous communication with the patient was important.The whole procedure would last for 3-4 hours.Criteria to terminate early were:
• Inability to visualize focal treatment spot.
• Patient complaints of unacceptable pain.
• Targeting difficulties due to patient motion.
After completing all the planned sonications,the last step was to assess the Nonperfused Volume by giving intravenous gadolinium as contrast.
Postprocedure
Following the procedure,the patient was taken to a holding area where the foley's catheter was removed.The skin surface would be examined for any heat induced changes.Body temperature would be recorded.Patient would be instructed not to drive and to take rest till se recovers from the sedation.She can resume activities the following day.The most common symptom was mild back pain,fever and general discomfort.Patient was discharged after one to two hours observation after the procedure.
Follow Up Of Patients
Patients were asked to come for follow up after 6 months and 12 months.They were given the same questionnaires regarding the improvement of symptoms.Their Hematocrit was measured and the values were noted.The fibroid shrinkage was assessed by clinical examination and Ultrasound pelvis. 
Representative Cases
IV. Results
Demographic Data: A total of 30 patients who underwent MR Guidedfocussed ultrasound therapy for fibroids at Bharat Scans between January 2014 and December 2014 over a period of 12 months, who fit the inclusion criteria were enrolled in this study.They underwent a preliminary screening MRI and those who were found to be eligible on screening were included in the study. The parameters measured were:
• Hematocrit.
• Menorrhagia scoring.
• Dysmenorrhea scoring.
• Pressure symptoms scoring.
• Immediate Nonperfused volume • Fibroid volume and fibroid shrinkage.
These parameters were measured at 6months and at the end of 12 months.The efficacy of mrgfus was defined as improvement in the haematocrit,symptom scoring and attaining >50%Nonperfused volume.Continuous data were represented by mean and standard deviation and categorical data were represented by frequencies and percentages and were analyzed. A value of p <0.05 was considered to be statistically significant. Data's were analyzed with SPSS 14.0 version. DOI: 10.9790/0853-1508060110 www.iosrjournals.org The paired sample test between the hematocrit values before and after treatment at 6 months and 12 months showed a statistically significant increase with a p value of <0.001. The paired sample test between the mean menorrhagia scoring before and after treatment at 6 months and 12 months was done and was found to be statistically significant with a p value <0.001. Table shows the mean dysmenorrhea score before and after treatment at 6 months and 12 months.There was a significant decline in the scoring with symptom improvement.
The mean baseline dysmenorrhea scoring decreased from 2.13 to 0.27.The paired sample The paired sample test between the mean dysmenorrhea scoring before and after treatment at 6 months and 12 months was done and was found to be statistically significant with a p value <0.001. Table shows the mean dysmenorrhea score before and after treatment at 6months and 12 months.There was a significant decline in the scoring withsymptom improvement.
The mean baseline pressure symptom scoring decreased from1.10 to 0.5. The paired sample test between the mean pressure symptom scoring before and after treatment at 6 months and 12 months was done and was found to be statistically significant with a p value <0.001. Table 5 shows that all fibroids that had a NPV ratio of >60% had a fibroid shrinkage of more than 30%.The values were analysed with chi square tests and were found to have a significant p value of <0.001. Table shows the influence of the number of fibroids and NPV ratio.It shows that only single fibroids could attain a better NPV ratio.The analysis of the values gave a significant p value of <0.05. 
CHI-SQUARE TEST
V. Discussion
This is a prospective studyconducted at Coimbatore medical college Hospital in collaboration with BHARATH SCANS during the period 2013-2014. The purpose of this study was to assess the effectiveness of MRgFUS in the treatment of uterinefibroids.In our study we had 30 eligible patients with symptomatic fibroids who met the inclusion criteria and were enrolled after a preliminary MRI screening.
Symptom severity scoring:
Symptoms like menorrhagia.dysmenorrhea,pressure symptoms and mass effect as reported by patients before,6 months and 12 months after treatment were assessed on a 4point scale with 0=none.1=mild,2=moderate and 3=severe. All the above mentioned SSS showed improvement and had a statistical significance with pvalue<.001,hence proving the hypothesis that MRgFUS treatment brings about significant and sustained improvement in symptoms.
Stewart EA et al conducted a study in 2007 and concluded that the symptom severity scoring significantly reduced from the baseline as early as 3 months. 
Hematocrit
In our study there was a mean increase in hematocrit from the baseline which was attributed to significant reduction in menorrhagia.
The mean values for hematocrit in our study: In our study of 30 patients,we had 22 fibroids of low intensity and 8 fibroids of high intensity, 100 percent of >60% NPV and 84.6 percent of 41-60% NPV were of low intensity fibroids. 75percent of high intensity fibroids attained only <40% NPV.These values were coinciding well with a p value of <0.001. Ronit et 
Acoustic Window
Among 30 patients in our study, 18 patients had no interference in the acoustic window. 6 patients had scars and 6 patients had some interference in the beam pathway lie bowel,other viscera.. 87.5% of >60% NPV ratio was attained only when there was no interference in the beam pathway.83% of NPV ratio <40% had some kind of interference in the form of scars,bowel or other viscera. Le Blang SD et al 2010 reported that factors limiting ablation were obstacles to passage of ultrasound beam like scars,bowel.
Nonperfused Volume Ratio.
The mean NPV ratio attained from a sample of 30 patients in our study is 48+ 14%.This is influenced by many factors like signal intensity of fibroid,number of fibroids,depth of fibroids and interference in the acoustic window. The Immediate NPV ratio attained correlated well with the symptom improvement and fibroid shrinkage. 
Fibroid Shrinkage
In our study the mean shrinkage of fibroid by the end of 6 months was 32%.These value correlated well with the IMMEDIATE NPV RATIO.
The values were analysedwith chi square tests and were found to have a significant p value of <0.05. Two patients had fever which comprised of 6.6%. Three patients had back pain which comprised of 10% of patients.There was no incidence of skin burns,sciatic nerve palsy. Taran FA et al in 2009 reported in his study of incidence of 2.8% of fever. Okada A et al in2009 reported postprocedure adverse events as follows:
Low back pain-8%,fever-6%,skin burns-1%,vaginal discharge-8%. Le Blang SD et al in 2010 showed that the incidence of minor sin burns was 2.5% and sciatica was 1.2%.
Any Additional Treatment
Among 30 patients in our study ,two of them opted out and went in for hysterectomy due to persistent symptoms especially the mass effect since the size of uterus was more than 16 weeks.This comprises of 6.6%.The hysterectomy specimen showed vast areas of necrosis. Taran FA et al in2009 reported a treatment failure rate of 3.7% Okada A et al showed that the rate of alternative treatment by the end of 12 months was 5%. Fenessey FM et al in 2007 showed that 28% sought alternative treatment . Gorny KR et al in 2011 reported that additional procedures for fibroid related symptoms within 1 year was 6.2%..
Summary:
➢ The sample studied was 30 women with symptomatic fibroids. ➢ Of these 19 had single fibroids and 11 had multiple fibroids. ➢ 22 were of low intensity and 8 were of high intensity fibroids on T 2 weighted MR images. ➢ There was a statistically significant decline in the symptom severity as per the symptom severity scoring for menorrhagia,dysmenorrhea,pressure symptoms and mass effect and discomfort. ➢ There was a ststistically significant improvement in the mean hematocrit.Te mean hematocrit increased from 28.4 to 33.07 wih a significant p value of <0.001. ➢ The mean NPV ratio attained in our study was 48.63+14% . ➢ The mean fibroid shrinkage attained by 6 months was about 32% which correlated well with the immediate NPV Ratio with a significant p value <0.001. ➢ Factors influencing NPV ratio were found to be signal intensity of fibroids,number of fibroids and any interference in the pathway of the ultrasound 
VI. Conclusion
Although hysterectomy has been the traditional treatment for uterine leiomyomas,there has been an upward trend towards the use of conservative ablative therapies with and without image guidance. MRgFUS has been tested and approved by the FDA and is a very successful noninvasive therapy particularly in those who demand a minimum treatment recovery time. From our study,there is evidence of improvements in the symptoms in patients treated with the MRgFUS, particularly for those presenting with symptoms of menorrhagia and dysmenorrhea.The symptom relief is sustained till one year. In respect of safety, MRgFUS resulted in very minor adverse events like fever,abdominaldiscomfort,backpain.There were no serious complications.
